A National Directory of Drug Treatment Centers and Alcohol Treatment Centers, Therapists and Specialists. A free, simple directory providing assistance and guidance for those seeking help regarding alcohol addiction, drug addiction, dependency and many other conditions that affect the mind, body and soul.
Call 800-580-9104 to speak with an alcohol or drug abuse counselor.

New Medications May Offer Hope to Drinkers Battling Alcohol Dependence

Individuals who experience the physical, mental and social symptoms associated with alcohol dependence are offered hope through the results of two recent studies by researchers at the Medical University of South Carolina (MUSC). In separate investigations, researchers found favorable results for a medication to help heavy drinkers who are trying to modify their consumption, as well as a medication to reduce alcohol withdrawal symptoms and prevent relapse.

In a landmark study, MUSC researchers working with investigators at the University of Virginia Health System and elsewhere have found that topiramate, an effective therapeutic medication, not only decreases heavy drinking, but it also lowers all liver enzymes, plasma cholesterol, body mass index (BMI), and systolic and diastolic blood pressure — all of which tend to increase with heavy drinking and pose such serious health risks as heart disease and cirrhosis. Notably, these combined effects suggest that topiramate may decrease the risk of heart disease in alcohol dependent individuals.

“These findings add growing data indicating that heavy drinkers who modify their drinking with the help of medication and supportive counseling may see an improvement in health and well-being, as well as a potential reduction of risk for the development of heart and liver diseases. This shows that treatment of alcoholism has potential health benefits beyond the immediate behavioral and emotional improvement caused by a reduction in drinking” said Raymond Anton, M.D., distinguished university professor.

By decreasing liver enzymes and cholesterol levels, topiramate also may reduce the risk of fatty liver disease, which leads to cirrhosis – a common consequence to end-stage liver disease leading to death in some alcoholics.

Additionally, topiramate significantly contributed to a decline in obsessive thoughts and compulsions, components of alcohol craving, and also had a greater improvement in their “overall quality of life,” and specifically an improvement in general and leisure activities and household duties, as well as a reduction in sleep disturbances.

The Food and Drug Administration has approved topiramate for seizures and migraine headaches, but it is not currently approved for treating alcohol dependence. Ortho-McNeil Neurologics, Inc., manufactures topiramate and provided study funding.

Results from the nationwide 14-week trial involving 371 male and female diagnosed alcoholics was published in the June 9 issue of the Archives of Internal Medicine.

In addition, Anton presented initial results from a separate investigation of a 14-week double-blind, placebo-controlled study utilizing the PROMETA ® alcoholism treatment program, developed by Hythiam, inc., at the 2008 Research Society on Alcoholism (RSA) conference in Washington D.C.

Anton suggested that alcohol dependence programs are few in number and not exceptionally effective, which is particularly true for individuals who experience alcohol withdrawal symptoms. PROMETA ®, a combination of generic medications, reduced cravings and alcohol withdrawal symptoms, promoted abstinence, and improved mood and sleep only in those who had symptoms of alcohol withdrawal. Although the PROMETA ® Protocol has been marketed nationally, this was the first scientific study examining its utility in individuals with alcohol dependence.

At the time of the RSA presentation, the data presented covered the initial six-week active treatment phase of the 14-week study. While these are initial findings, additional evaluation of the full 14-week study data is ongoing, and Anton plans to release these specifics in a peer-reviewed publication.

MUSC has an ongoing clinical trial program studying new medications for the treatment of alcohol use disorders. For more information call 843-792-2727.
__________
source: Newswise Medical News

More Treatment & Detox Articles

Center will study effects of alcohol on brain

UNM was given $2.5 million this semester to start one of the nation’s first fetal alcohol research centers. The program is funded by a five-year grant from the National Institute on Alcohol Abuse and Alcoholism. The New Mexico Alcohol Research Center will look at the effects of alcohol on the brain. Dr. Daniel Savage, who….

Continue reading

Alcoholism Treatment Centers for Lasting Recovery

Deciding to seek help for alcoholism is the very first step to finally recovering from a dangerous and deadly addiction to alcohol, but it’s also one of the most difficult decisions you will ever make. Choosing between the many alcoholism treatment centers that are available to help you or a loved one overcome addiction is….

Continue reading

Scots are drinking themselves into early grave

Scots are drinking themselves to death faster than Ever as the nation’s disturbing booze-binge culture starts to take its toll among thirtysomethings. Hospitals are now being swamped with more than 100 patients needing treatment for alcohol-related conditions Every Day, the frightening new NHS figures show. Liver disease has trebled in the past 15 years. But….

Continue reading

Time for Drug Treatment to Rattle Its Saber

In an effort to recast substance abuse as more of a public health problem than a crime, the nation’s newly appointed drug czar has called for an end to talk of a “war on drugs.” “Regardless of how you try to explain to people it’s a ‘war on drugs’ or a ‘war on a product,’….

Continue reading

Exercise may fight addiction

New approaches for treating and preventing drug addiction range from low-tech – regular exercise – to high-tech such as experimental vaccines aimed at helping to prevent former drug users from relapsing. Nora Volkow, director of the National Institute on Drug Abuse, is just as excited about both options. Of the two, though, exercise will probably….

Continue reading